J05AR03 • emtricitabine + tenofovir disoproxil • Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations
The combination of emtricitabine and tenofovir disoproxil is used for the treatment of HIV infection and for pre-exposure prophylaxis (PrEP). It works by inhibiting reverse transcriptase, preventing HIV replication.
The medication is taken orally, usually once daily, with the dose adjusted based on the patient's weight and renal function. Common side effects include nausea, diarrhea, headaches, and decreased bone mineral density.
This combination is contraindicated in patients with severe renal impairment or hypersensitivity to any of the components. Its use also requires regular monitoring of renal function and bone density.
This medication is an effective option for managing HIV infection and preventing virus transmission, helping to improve patients' quality of life.
Substance: emtricitabine + tenofovir disoproxil
Date of last drug list: 01-05-2026
Commercial code: W62931007
Concentration: 200mg / 245mg
Pharmaceutical form: film-coated tablets
Quantity: 30
Product type: generic
Price: 282.22 RON
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: PLIVA HRVATSKA D.O.O. (PLIVA CROATIA LTD.) - CROATIA
Holder: TEVA PHARMACEUTICALS S.R.L. - ROMANIA
Number: 13984/2021/01
Shelf life: 2 years; after openinga flaconului- 30 days
NHP 1.A (C2) - People with HIV/AIDS and post-exposure treatment
Price
Copayment
Patient
282.22 RON
282.22 RON
0.00 RON